Pegylated Mechano Growth Factor — synthetic Ec splice variant of IGF-1 with PEGylation for extended half-life. Local muscle stem-cell activation and tissue repair signaling.
Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
MGF (IGF-1Ec) is the splice variant produced locally in muscle in response to mechanical stress. PEGylation extends the otherwise minutes-long half-life. Preclinical models show satellite cell proliferation and accelerated regeneration after injury. No human clinical trials. Often paired with IGF-1 LR3 in physique-community stacks; often counterfeit in grey market.
No human safety data. Local IGF-1 axis activation creates unknown long-term tissue-overgrowth and cancer-promotion concerns. Identity verification of grey-market product is poor — PEG-MGF is among the most counterfeited peptides.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 100-200 µg · post-workout, intramuscular at target site
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Expected reclassification — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.